UK increases scrutiny of tech and life sciences deals
Paolo Palmigiano explains why mergers and acquisitions in the tech and life sciences sectors may be subject to closer scrutiny by the UK competition authority and by the UK government in future.
More 
US buys up entire stock of remdesivir
After the US was reported to have bought the entire stock of remdesivir from producer Gilead, Judith Krens asks whether there are ways to intervene in the Netherlands (and in other European countries). More
Dissecting the Regeneron v Kymab mouse case
Adrian Toutoungi, Matthew Royle and Paul England discuss whether this case has shifted the boundaries of patent protection, or merely clarified the status quo. More
Private equity investment in life sciences sector
Our experts explore some of the potential benefits and challenges for life sciences companies considering private equity investment from the perspective of investee companies. More
Patent diary – July 2020: Court refuses to strike out Chiesi's quia timet injunction claim
Paul England reports on the Patent Court's refusal to strike out a quia timet injunction claimed by Chiesi against Teva. More
Territorial licensing: "start at the end before you begin"
Colin McCall and Justyna Ostrowska explain how territorial licences can be a great way to get your product on the market, and why it's still not enough to sign off the rights and wait for the royalties to come in. More
Too sweet to throw away? Sweetened/carbonated beverages industry law changes in Poland
Agata Głowinkowska and Agnieszka Sztoldman explain important new rules for the food and beverage industry. More
Arbitration for life sciences companies
Laurence Lieberman, Tasmina Goraya and Colin McCall set out some of the reasons why arbitration can be an attractive alternative for life sciences companies when resolving their contract disputes. More
∨ More Topical Issues
Patent pools - an easy licensing option?
Privacy regulator guidance in light of COVID-19
Patents diary June 2020: UK Supreme Court holds Regeneron's transgenic mice patents invalid
Legal advice privilege: where are we now?
Impact of COVID-19 on venture-backed biotech companies
A Czech perspective on COVID-19 and healthcare law
COVID-19 and public compulsory licensing of drugs in Europe
NHS can procure drugs for use outside of their approved indications if it's cheaper, court says
The deadlock on the Unified Patent Court – a full analysis
Personal protective equipment COVID-19 export restrictions
The Bolar and related exemptions in Europe: What activity do they cover?
Right of access to documents in marketing authorisation applications confirmed
Lower maximum prices of medicines as of April 2020
Medical devices and managing product liability risks
Clash of IP and competition to pharma's detriment? The CJEU's decision in the GSK case
To Neurim or not to Neurim, that is the question
Changes in the industrial property law of Poland
Pricing: highlights of the J.P. Morgan Healthcare Conference
Life sciences products after Brexit: the transition period
Coming this year: A User's Guide to Intellectual Property in the Life Sciences
An ius comune of European Patent Law
No automatic compensation for a wrongful PI, rules the CJEU
SPC manufacturing waiver (Part 2)
Poland changes course on its Bolar provision
A way into the UPC for post-Brexit Britain?
Taking a new approach to European patent law
New draft regulations on advertising of medical devices in Poland
Patenting of gene and protein sequences: an EU and US perspective
Biosimilars – Clearing the way for launch
First Dutch GDPR fine for failing to ensure security of patient files
Dr Bill Frankland: Penicillin, the pollen count and perspectives on medicine
Managing cybersecurity risk: a life sciences perspective
CJEU ruling to liberalise parallel import in Poland
Dutch court holds pemetrexed tromethamine does not infringe patent for pemetrexed disodium
Pharmacy preparations in The Netherlands
Webinar: Recent legislative developments affecting biologics and biosimilars
Webinar: Recent legislative developments affecting biologics and biosimilars
Webinar: Recent legislative developments affecting biologics and biosimilars
SPC manufacturing waiver for export and stockpiling comes into force
No compulsory licence for Sanofi's Praluent in Germany
The Court of Justice on skinny labels
The UK Supreme Court rules on inventive step
Brexit update – 'Grandfathering' marketing authorisations
SPC for darunavir considered invalid in Dutch preliminary relief proceedings
Essentially biological processes and their products – what is patentable?
Falsified Medicine Directive continued
SPC for ezetimibe/simvastatin considered invalid
Plausibility of second medical use patents: pregabalin in the Supreme Court
Infringement of second medical use patents in the UK
The grant of an SPC for a new therapeutic application
Prescription to patenting: cannabis-derived medicinal products
High Court considers meaning of "defect" under the Consumer Protection Act 1987
Tailored injunctive relief in life sciences patent cases
Who owns editorial control over the code of life? An update on CRISPR
SmPC 'carve out' limits marketing authorisation
Life Sciences Organisation sets out the UK stall
New government code of conduct for data-driven technologies in the health and care industries
Brexit and the life sciences sector: the UK Government’s offer to the EU
Brexit and the life sciences sector: guidelines for 'no deal'
Patents Court rules SPC invalid in Truvada case
Dutch competition authority ACM starts sector inquiry into anti-rheumatism drugs
The UK has ratified the UPC Agreement
Dutch Supreme Court ruling on claim interpretation in Resolution v AstraZeneca
AI and big data in the healthcare sector
New trade secrets law takes effect in UK
Choosing the right space for life science success
GC finds Normon similar to Normosang for pharmaceuticals
Brexit and the life sciences: April 2018 update
The UPC and Unitary Patent: April 2018 update
Possible ban on the mail-order of prescription-only (Rx) medicinal products in Germany
Dutch competition authority ACM targets pharmacy sector in 2018-2019
UK government announces review responding to patient concerns about three NHS treatments
Brexit and Beyond – Wellcome's recommendations from the Future Partnership
Supplementary Protection Certificates 1: what products can be protected by an SPC?
Licence held to be exclusive despite option
Latest developments on UK ratification of the UPC
Failure to date references in advertisement violates German Drug Advertising Act
Unjustified threats of patent infringement – changes to UK law
CJEU rules no authorisation of health claims made on glucose
Fujifilm declarations – High Court rules in favour of FKB in Humira® challenge
Rezeptortyrosinkinase II: Patent protection for a test method does not extend to test results
Data and market exclusivity in pharmaceuticals
The UK backs the UPC and Unitary Patent
Largest single Biomedical Laboratory in Europe opened by Queen
IP Indemnities in commercial agreements
Calculation of SPC term in EU accession countries
Data exclusivity for innovators - a bridge too far?
Damages in Trade Secrets Cases - "Derived Products"
A missed chance – The CJEU’s ruling on calculation of damages
CJEU confirms orphan drug market exclusivity
European trade mark reform: all change from 23 March 2016
Biosimilars and the issue of duplicates
Intellectual Property in the Life Sciences, in review
High Court grants declaratory relief in pharmaceutical regulatory dispute
BGW Federal Association of Health Industry trade mark contested
The implementation of the Nagoya Protocol in the EU
The implementation of the Nagoya Protocol in Germany
Supreme Court ruling on penalty clauses
Upgrading the single market: updating the Bolar exemption
Upgrading the single market: SPC manufacturing waiver
Managing IT projects in the healthcare sector - a European perspective
Facing up to antimicrobial resistance – recommendations from the O'Neill review
Largest damages award on cross-undertaking upheld on appeal
Strategic considerations - why opt-out or why not?
Pharmaceutical trade mark confusion
Using intellectual property protection
EU Commission regulates post-authorisation efficacy studies
Renewing your lease: know your rights and don't get caught out!
What types of funding are typically available for an early stage life sciences company?
What are the sources of funding for early stage life sciences companies?
Personalised Medicine – challenges of authorisation and reimbursement
Topical Issues
Topical issues connects you with information and analysis on the most important legal and regulatory developments that you need to know about. Written by our team of experts, they explain in commercially relevant terms how these issues will impact upon the life sciences sector now and in the future.